EIDD-2801, a new antiviral drug, has the potential to treat coronavirus. A new study reveals the drug can prevent severe lung injury in mouse models and cultured human lung cells infected with COVID-19. The drug will soon be ready for human testing.
Researchers have isolated a set of antibodies from a llama which show promise for the treatment of COVID-19. The NIH-CoVnB-112 nanoantibody bound to ACE2 receptors up to ten times stronger than other lab-produced antibodies. The nanoantibody stuck directly to the ACE2 receptor binding portion of the SARS_CoV-2 spike protein. The protein could be effective in preventing coronavirus infection.
Researchers have developed a new paper device that can be put into wastewater systems to detect COVID-19. The test works by picking up on biomarkers of the virus in feces and urine. The test can help monitor communities most at risk of the virus and help agencies to restrict the movement of the population at risk.
Findings suggest cell-to-cell transmission of cGAMP via LRRC8/VRAC ion channels is central to effective antiviral immunity.
A drug used to treat feline infectious peritonitis, an often fatal coronavirus infection in cats, may hold the key for developing a treatment for human COVID-19.
Microglia help limit infection to the olfactory bulb and protects neurons from damage that could occur as a result of viral infection.
A new small scale study reveals the antidepressant fluvoxamine may be a new tool in the fight against COVID-19. Researchers report fluvoxamine reduced the severity of coronavirus symptoms and hospitalizations.
The first round of antibody testing in L.A country reveals approximately 4.1% of the adult population has COVID-19 antibodies. Adjusting for margin of error, between 2.8% to 5.6% of the adult population has antibodies to the virus. This means between 221,000 and 442,000 adults in the Los Angeles area have been infected with coronavirus. The estimate is up to 55 times higher than confirmed cases reported for the area.
COVID-19 can spark a severe immune response in the central nervous system, affecting immune cells in the vascular system and brain.
People who experience "brain fog" and other neurological problems following COVID-19 infection may be suffering from PTSD, researchers report.